Ruijin Hospital

Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer

Phase 2, Recruiting, 2025, 28 people, 9 Oct 2026, clinicaltrials.gov

NCT07838714

Phase 1, Recruiting, 2026, 18 people, 24 Sept 2026, clinicaltrials.gov

NCT07735117

Phase 3, Not yet recruiting, 2026, 168 people, 29 Jul 2026, clinicaltrials.gov

NCT07719855

Phase 3, Not yet recruiting, 2026, 652 people, 22 Jul 2026, clinicaltrials.gov

NCT07680595

Phase 1/2, Recruiting, 2026, 180 people, 2 Jul 2026, clinicaltrials.gov

NCT07638787

Phase 1/2, Not yet recruiting, 2026, 40 people, 10 Jun 2026, clinicaltrials.gov

NCT07594899

Phase 2, Not yet recruiting, 2026, 178 people, 19 May 2026, clinicaltrials.gov

NCT07569068

Phase 2, Recruiting, 2026, 88 people, 6 May 2026, clinicaltrials.gov

NCT07384234

Phase 2, Recruiting, 2026, 60 people, 3 Feb 2026, clinicaltrials.gov

NCT07366528

Phase 3, Recruiting, 2025, 387 people, 26 Jan 2026, clinicaltrials.gov

NCT07310433

Collaborator, Phase 2, Not yet recruiting, 2026, 60 people, 30 Dec 2025, clinicaltrials.gov

NCT07301138

Phase 2, Not yet recruiting, 2025, 23 people, 24 Dec 2025, clinicaltrials.gov

NCT07265349

Collaborator, Phase 1/2, Recruiting, 2025, 51 people, 4 Dec 2025, clinicaltrials.gov

NCT07025889

Phase 1/2, Recruiting, 2025, 55 people, 18 Jun 2025, clinicaltrials.gov

NCT06972641

Phase 2/3, Recruiting, 2025, 126 people, 15 May 2025, clinicaltrials.gov

NCT06968208

Phase 2, Not yet recruiting, 2025, 80 people, 13 May 2025, clinicaltrials.gov

NCT06803693

Phase 2, Recruiting, 2025, 152 people, 31 Jan 2025, clinicaltrials.gov

NCT06802926

Phase 4, Recruiting, 2025, 100 people, 31 Jan 2025, clinicaltrials.gov

NCT06765928

Phase 2, Not yet recruiting, 2025, 73 people, 9 Jan 2025, clinicaltrials.gov

NCT06701344

Phase 2, Not yet recruiting, 2024, 7 people, 22 Nov 2024, clinicaltrials.gov